Paul Stephen Wissel

机构：Pfizer (United States), University of Pennsylvania · ORCID：0000-0002-5790-8875

发表论文 71 篇 · 总被引 1933 次 · h-index 23

代表论文

• Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer (2006 · Journal of Clinical Oncology · 被引 146)
• Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS ‐mutant relapsed or refractory myeloid malignancies (2016 · Cancer · 被引 145)
• Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer (2023 · Journal of Clinical Oncology · 被引 126)
• Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study (2015 · Journal of Clinical Oncology · 被引 106)
• A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors (2004 · Cancer Chemotherapy and Pharmacology · 被引 106)
• Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein (1999 · Anti-Cancer Drugs · 被引 95)